A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy.
Journal
Medicina oral, patologia oral y cirugia bucal
ISSN: 1698-6946
Titre abrégé: Med Oral Patol Oral Cir Bucal
Pays: Spain
ID NLM: 101231694
Informations de publication
Date de publication:
01 Jul 2021
01 Jul 2021
Historique:
received:
15
09
2020
accepted:
30
11
2020
pubmed:
20
12
2020
medline:
3
7
2021
entrez:
19
12
2020
Statut:
epublish
Résumé
Incidence of Medication-Related Osteonecrosis of the Jaw (MRONJ) related to cancer and myeloma treatments is undetermined, with scarce data varying from 2 to 7.8/million/year in limited investigated populations. A 9-years [2009-2018] regional-wide survey was conducted, deploying the North-Western Italy Cancer Network ("Rete Oncologica Piemonte e Valle d'Aosta"), to assess number and main characteristics of MRONJ cases among myeloma/cancer patients, within a population of 4.5 million inhabitants. MRONJ cases were collected retrospectively from January 2009 to June 2015; from July 2015 to December 2018, data were collected prospectively. Number of new MRONJ cases per year, underlying disorder, drug(s) administered, treatment duration, site and onset timing of MRONJ were detailed. 459 MRONJ cases were identified. Primary diseases were breast cancer (46%), prostate cancer (21%), myeloma (19%), and other types of carcinoma (14%). Patients received antiresorptive treatment either alone (399; 88.47%) or in combination with biological agents (52; 11.53%); 8 patients (1.7%) received only antiangiogenic drugs. Zoledronic acid [388] and denosumab [59] were the most frequently administered drugs. Mandible was involved in 296 (64,5%) cases. Number of new MRONJ cases was stable from 2009 to 2015, with a mean of 51.3 cases per year (raw incidence: 11.6/million/year), declining in the 2016-2018 years to 33.3 cases per year (raw incidence: 7.5/million/year). With such discrepancy of cases overtime being partially explicable, number of new MRONJ cases per year are consistent with those observed in a previous study [2003-2008] in the same region, being instead higher than those reported in other populations.
Sections du résumé
BACKGROUND
BACKGROUND
Incidence of Medication-Related Osteonecrosis of the Jaw (MRONJ) related to cancer and myeloma treatments is undetermined, with scarce data varying from 2 to 7.8/million/year in limited investigated populations. A 9-years [2009-2018] regional-wide survey was conducted, deploying the North-Western Italy Cancer Network ("Rete Oncologica Piemonte e Valle d'Aosta"), to assess number and main characteristics of MRONJ cases among myeloma/cancer patients, within a population of 4.5 million inhabitants.
MATERIAL AND METHODS
METHODS
MRONJ cases were collected retrospectively from January 2009 to June 2015; from July 2015 to December 2018, data were collected prospectively. Number of new MRONJ cases per year, underlying disorder, drug(s) administered, treatment duration, site and onset timing of MRONJ were detailed.
RESULTS
RESULTS
459 MRONJ cases were identified. Primary diseases were breast cancer (46%), prostate cancer (21%), myeloma (19%), and other types of carcinoma (14%). Patients received antiresorptive treatment either alone (399; 88.47%) or in combination with biological agents (52; 11.53%); 8 patients (1.7%) received only antiangiogenic drugs. Zoledronic acid [388] and denosumab [59] were the most frequently administered drugs. Mandible was involved in 296 (64,5%) cases. Number of new MRONJ cases was stable from 2009 to 2015, with a mean of 51.3 cases per year (raw incidence: 11.6/million/year), declining in the 2016-2018 years to 33.3 cases per year (raw incidence: 7.5/million/year).
CONCLUSIONS
CONCLUSIONS
With such discrepancy of cases overtime being partially explicable, number of new MRONJ cases per year are consistent with those observed in a previous study [2003-2008] in the same region, being instead higher than those reported in other populations.
Identifiants
pubmed: 33340073
pii: 24318
doi: 10.4317/medoral.24318
pmc: PMC8254890
doi:
Substances chimiques
Bone Density Conservation Agents
0
Diphosphonates
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e466-e473Références
BMJ Open. 2019 May 22;9(5):e025600
pubmed: 31122970
J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56
pubmed: 25234529
J Clin Oncol. 2017 Dec 10;35(35):3978-3986
pubmed: 29035643
Support Care Cancer. 2017 Feb;25(2):345-349
pubmed: 26961666
J Clin Endocrinol Metab. 2015 Oct;100(10):3887-93
pubmed: 26241323
J Craniomaxillofac Surg. 2018 Sep;46(9):1515-1525
pubmed: 29983309
Clin Epidemiol. 2016 Jul 20;8:267-72
pubmed: 27499646
J Oral Maxillofac Surg. 2007 Mar;65(3):415-23
pubmed: 17307586
Osteoporos Int. 2013 Jan;24(1):237-44
pubmed: 22707065
Oral Dis. 2012 Sep;18(6):621-3
pubmed: 22353421
J Oral Maxillofac Surg. 2018 Oct;76(10):2105-2112
pubmed: 29746838
Oncologist. 2011;16(1):121-32
pubmed: 21212433
Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 Dec;126(6):477-485
pubmed: 30249535
Clin Epidemiol. 2013;5:1-7
pubmed: 23323023
Ther Clin Risk Manag. 2018 Dec 24;15:59-64
pubmed: 30636879
Clin Epidemiol. 2015 Jan 30;7:107-16
pubmed: 25657594
Acta Clin Belg. 2018 Apr;73(2):100-109
pubmed: 28693379
ISRN Oncol. 2013;2013:672027
pubmed: 23533811
Bratisl Lek Listy. 2017;118(12):724-731
pubmed: 29322803
J Korean Assoc Oral Maxillofac Surg. 2013 Feb;39(1):9-13
pubmed: 24471011
Br J Oral Maxillofac Surg. 2015 Feb;53(2):176-82
pubmed: 25497376
Acta Odontol Scand. 2013 Nov;71(6):1386-90
pubmed: 23351164
J Bone Miner Res. 2015 Jun;30(6):1113-5
pubmed: 25988662
Cancer Med. 2017 Oct;6(10):2271-2277
pubmed: 28941210
Lancet Oncol. 2013 Jun;14(7):663-70
pubmed: 23684411